New IBD drug candidate PVT401 enters first human safety trial
Knowledge-focused
Recruiting now
This early-stage study tests the safety of a new drug called PVT401 in 36 healthy volunteers. The drug is being developed for inflammatory bowel disease (IBD). Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through t…
Phase: PHASE1 • Sponsor: Parvus Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 13, 2026 16:01 UTC